Financial Performance - The company's revenue for Q1 2024 was CNY 76,119,952.75, representing a 7.40% increase compared to CNY 70,874,328.77 in the same period last year[5] - Net profit attributable to shareholders increased by 75.58% to CNY 10,707,388.40 from CNY 6,098,289.41 year-on-year[5] - The company reported a basic earnings per share of CNY 0.1073, up 31.98% from CNY 0.0813 in the previous year[5] - Operating profit for Q1 2024 was CNY 10,618,920.79, compared to CNY 6,501,060.65 in Q1 2023, marking a growth of 63.5%[21] - Net profit for Q1 2024 reached CNY 10,707,388.40, a significant increase of 75.5% from CNY 6,098,289.41 in Q1 2023[22] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1073, compared to CNY 0.0813 in Q1 2023, reflecting an increase of 32.5%[22] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 37,498,382.94, a 169.41% increase from a negative CNY 54,023,970.05 in Q1 2023[8] - Cash flow from operating activities totaled CNY 269,434,763.64 in Q1 2024, compared to CNY 168,284,597.45 in Q1 2023, indicating a growth of 60.1%[23] - The net increase in cash and cash equivalents was CNY 54,495,877.02, a 368.52% rise compared to a decrease of CNY 20,294,770.54 in the same period last year[8] - Total cash and cash equivalents at the end of Q1 2024 reached ¥694,758,375.54, up from ¥99,070,915.70 at the end of Q1 2023, reflecting a net increase of ¥54,495,877.02 during the quarter[24] - The company reported a cash flow from financing activities net increase of ¥31,125,241.77 in Q1 2024, compared to a net increase of ¥40,727,861.27 in Q1 2023, showing a decrease in financing activity[24] Assets and Liabilities - Total assets increased by 3.17% to CNY 2,059,975,220.03 compared to CNY 1,996,714,366.68 at the end of the previous year[5] - The company’s total liabilities increased to CNY 1.02 billion from CNY 1.00 billion, reflecting a growth of approximately 2.0%[17] - The company’s equity attributable to shareholders reached CNY 1.04 billion, up from CNY 0.99 billion, indicating an increase of about 5.1%[17] - The company’s short-term borrowings increased by 41.58% to CNY 154,471,657.31, attributed to new bank loans[8] - Total liabilities as of Q1 2024 were CNY 733,953,963.45, an increase from CNY 667,983,925.64 in the previous year[21] Operational Efficiency - The company received government subsidies amounting to CNY 230,391.82 during the quarter, contributing to its financial performance[6] - The company reported a significant increase in cash received from sales of goods and services, amounting to CNY 257,093,414.86 in Q1 2024, compared to CNY 160,497,602.16 in Q1 2023[23] - Cash outflow from investing activities was ¥14,128,274.13 in Q1 2024, compared to ¥6,989,528.60 in Q1 2023, indicating increased investment in long-term assets[24] - The total cash outflow for operating activities was ¥231,936,380.70 in Q1 2024, slightly higher than ¥222,308,567.50 in Q1 2023, indicating stable operational costs[24] Changes in Accounting and Reporting - The company did not undergo an audit for the Q1 2024 report, which may affect the perception of financial reliability[26] - The company has adopted new accounting standards starting from 2024, which may impact future financial reporting and analysis[25] Research and Development - Research and development expenses for Q1 2024 were CNY 5,265,641.53, down from CNY 7,160,670.59 in Q1 2023, a decrease of 26.5%[21]
港通医疗(301515) - 2024 Q1 - 季度财报